Package of Weight Loss Drugs Wagovi, Ozmpic and Maunjaro.
Picture alliance | Getty images
Increasing demand for diabetes and weight loss drugs such as Maunzaro, Ozmpic and Vagovi has helped fuel high health costs for large employers. For many people, the big question is whether the activities known as GLP-1S will make worker improvements and pay overall health cost over time. Aon analysts say this is already happening.
“We have never seen anything like that, in fact,” Greg case said, CEO CEO AonAn employer benefits the benefit service firm. “There was a decrease of 44% in major cardiovascular issues. Osteoporosis decreased significantly. Many types of pneumonia had decreased significantly.”
Researchers at AON found that within two years, better health results for patients taking GLP -1 drugs bow to the cost curve on medical care for them and their employers. However, high advance costs are required to achieve those savings.
GLP-1s per dose comes at a list of more than $ 1,000. There is high demand for widespread approval for drugs, this is also increasing the cost of employer drug. Since 2023, GLP-1s have increased the cost compared to high-priced special drugs, including expensive cancer and autoimmune remedies, Analysis By Evernorth, a division Signa,
AON analysts saw medical claims data for 139,000 US -based workers with employer health coverage, who took GLP -1 between 2022 and 2024. Beyond the cost of the drug, the study found that GLP -1 patients do to provoke high medical costs on drugs in their first year, and more doctors compared to and other issues such as sleep AP and Essophagis like acid.
“The growth comes in the first 12 to 15 months,” the case said. “They are receiving treatment on things that are actually underlying conditions [of obesity],
But by the end of the second year of treatment with GLP -1 drugs, the cost of total health care for patients taking them fell 7% on average, compared to workers with similar chronic conditions and features of obesity, AON found. Savings were up to 13%for GLP-1 patients who maintained harsh adherence for pharmaceutical diet.
The largest driver of savings, who were not taking patients, were more than 40% of the major adverse cardiovascular events such as heart attacks and strokes compared to patients who were not taking drugs, as well as a decrease in the onset of diabetes.
The case with this data said, apart from Aon Type 2 diabetes, providing insurance coverage for weight loss is able to help customers understand the timeline to see the return on providing a return.
“We saw every place where the cost reduced – and it’s amazing,” the case said. “You can do it in such a way that has an ROI, which will really be an economic return.”
After its research, Aon has launched a subsidized GLP-1 weight management program for its own American workforce, which includes weekly virtual wellness visits and home blood tests, which help employees to follow drug regimen.
The company will present full results of its study at the Milken Institute Global Conference on Monday.
